About us - Modus Therapeutics

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits.

Sevuparin, a heparinoid, has been designed to retain its inflammation modifying properties while causing significantly less blood-thinning. As a result, sevuparin can be dosed at significantly higher levels than other comparable heparinoids, allowing it to be used to treat multiple diseases that are caused by severe inflammation.

Thanks to its unique properties and a confirmed safety profile, sevuparin has the potential to greatly improve the treatment of sepsis/septic shock and other conditions with acute systemic inflammation for example severe trauma, burns, major surgery, and severe malaria. Furthermore, the properties of sevuparin could also address states of anemia that are related to chronic inflammatory diseases such as kidney disease.

Modus' largest owners are Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (jointly owned by Karolinska Development AB and Rosetta Capital) and John Öhd. The company has been listed on the Nasdaq First North Growth Market since July 2021.

Modus business model

An important part of Modus’ strategy is to attract partnerships and buyers for sevuparin by creating product value in our clinical research. We believe that product value is best created through robust clinical data with value-building milestones to enable further value build with a partner that already has presence in the therapy area and its market. A significant such milestone is after the completion of the phase IIa patient study by the end of 2023. Modus definitely has the ability to drive development of sevuparin all the way to registration thanks to the combined experience of our team, supported by consultants who followed Modus for the past 10 years, and our scientific advisors. However, Modus believes that there is more benefit to the value development for a project like this to come under the attention of partner who can drive market entry through an established market structure. Our business model is therefore based primarily on partnership. In the current development plan, a product approval/ NDA (New Drug Application) can be implemented around the shift 2028/2029.

Modus’ business model is supported by its risk diversified project portfolio that has the potential to appeal to partners with different interests and strategies.

To obtain market support for a registration, two large Phase III studies with a total of more than 1,000 patients over a more extended period are typically required. Given that there is no approved adjunctive drug for sepsis or severe malaria and the severe nature of these indications, sevuparin may be eligible for certain reliefs/privileges in the authorities’ assessment processes. Several FDA and EMA programs potentially facilitating development may therefore be available to these programs.

Blood Cells

LEADERSHIP TEAM & BOARD

John Öhd, M.D., Ph.D. Chief Executive Officer

Claes Lindblad CFO & Head of IR

Viktor Drvota, M.D, Ph.D Chairman / CEO, Karolinska Development

Johan Dighed Deputy CEO and general counsel at Karolinska Development AB

Ellen K. Donnelly, Ph.D. CEO, Abliva AB

KEY SCIENTIFIC ADVISORS

Lennart Lindbom

Eddie Weitzberg

Mats Wahlgren